Vorinostat enhances the antimyeloma effects of melphalan and bortezomib

European Journal of Haematology
Richard A CampbellJames R Berenson

Abstract

Examine the antitumor activity of the histone deacetylase inhibitor vorinostat's antitumor activity against multiple myeloma (MM) using cell lines and a murine xenograft model. RPMI8226, U266, and MM1S cells were cultured for 48 h in the presence of media, vorinostat, melphalan, or bortezomib alone, or combinations of vorinostat with melphalan or bortezomib. Cell proliferation was measured using the MTS [3-(4,5-dimethylthiazol-2yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfphophenyl)-2H-tetrazolium, inner salt] assay. Severe combined immunodeficient mice bearing LAGkappa-1B tumors were treated with vorinostat [30, 60, or 100 mg/kg daily for five consecutive days per week (qdx5d), 100 or 300 mg/kg daily for 2 d/wk (qdx2d)], melphalan (1, 3, or 10 mg/kg qdx1d), bortezomib (0.25 or 0.5 mg/kg qdx2d), or combinations thereof for 35 d. Tumor growth was determined via measurement of human immunoglobulin G (hIgG) levels and tumor volume. Vorinostat enhanced the anti-MM effects of melphalan and bortezomib in vitro. Synergism was observed with vorinostat and melphalan in RPMI8226 and U266 cell lines. Vorinostat 100 mg/kg in combination with melphalan 3 mg/kg resulted in significant inhibition of tumor growth in vivo, compared with control (tum...Continue Reading

References

Apr 18, 1998·Proceedings of the National Academy of Sciences of the United States of America·A Ciechanover, A L Schwartz
Aug 3, 2000·Journal of the National Cancer Institute·P A MarksR A Rifkind
Mar 21, 2002·Nature Reviews. Cancer·P MarksW K Kelly
May 4, 2004·Nature Reviews. Cancer·Julian Adams
May 22, 2004·Neoplasia : an International Journal for Oncology Research·Annamaria BiroccioGabriella Zupi
Oct 29, 2004·The New England Journal of Medicine·Robert A Kyle, S Vincent Rajkumar
May 18, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·William Kevin KellyVictoria M Richon
Jun 7, 2005·Proceedings of the National Academy of Sciences of the United States of America·Teru HideshimaKenneth C Anderson
Apr 18, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Bhupinder S MannRichard Pazdur
May 15, 2007·Biochemical Pharmacology·Keith B Glaser
May 19, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Suresh S RamalingamChandra P Belani
Dec 21, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Valeria R Fantin, Victoria M Richon
Feb 22, 2008·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
Mar 12, 2008·Blood·Robert A Kyle, S Vincent Rajkumar
Nov 15, 2008·Current Oncology·D R Walkinshaw, X J Yang
Aug 12, 2009·Journal of Pain & Palliative Care Pharmacotherapy·UNKNOWN U.S. Food and Drug Administration
Aug 20, 2010·Journal of Pain & Palliative Care Pharmacotherapy·UNKNOWN U.S. Food And Drug Administration

❮ Previous
Next ❯

Citations

Dec 2, 2010·Investigational New Drugs·Enrique M Ocio, Jesús F San Miguel
Aug 27, 2013·Bone·Meghan E McGee-Lawrence, Jennifer J Westendorf
Apr 26, 2013·Leukemia & Lymphoma·Roman HajekMeletios Dimopoulos
Jun 11, 2015·British Journal of Haematology·Douglas W SborovCraig C Hofmeister
Jun 22, 2013·Clinical Lymphoma, Myeloma & Leukemia·Jonathan L KaufmanPaul G Richardson
Jan 20, 2017·Pharmaceutical Research·Charvi Nanavati, Donald E Mager
Dec 4, 2014·Therapeutic Advances in Hematology·Claudia V Andreu-Vieyra, James R Berenson
Aug 1, 2011·Therapeutic Advances in Hematology·Saad A Khan, Adam D Cohen
Aug 19, 2014·Bone Marrow Transplantation·P J ShawH M Lazarus
Aug 6, 2011·Clinical Journal of Oncology Nursing·Teresa S MiceliUNKNOWN International Myeloma Foundation Nurse Leadership Board
Nov 19, 2010·Expert Review of Hematology·Ramón García-Sanz, Enrique M Ocio
Oct 19, 2017·CPT: Pharmacometrics & Systems Pharmacology·Charvi NanavatiDonald E Mager
Jun 26, 2020·Frontiers in Cell and Developmental Biology·Linda Anna Michelle KulkaHeidi Olzscha
Mar 29, 2013·Molecular Cancer Therapeutics·Holly A F StessmanBrian G Van Ness
Jan 27, 2017·Molecular Cancer Research : MCR·Haiming ChenJames R Berenson
May 20, 2016·Molecular Cancer Therapeutics·Nicola AmodioPierfrancesco Tassone

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.